Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Christy M. Hebner"'
Autor:
Maria L Agostini, Gretja Schnell, Julia di Iulio, Anita Kohli, Adrienne E Shapiro, Elias H Sarkis, Dave Inman, Amanda Peppercorn, Andrew Skingsley, Leah A Gaffney, Melissa Aldinger, Christy M Hebner, Andrea L Cathcart
Publikováno v:
Open Forum Infectious Diseases. 9
Background Sotrovimab (VIR-7831) is an engineered human monoclonal antibody targeting a conserved region of the SARS-CoV-2 spike protein; it has been shown to have a favorable safety profile and be effective for early treatment of high-risk COVID-19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eaee9d60bad49ab049db89a91026ce55
https://doi.org/10.1093/ofid/ofac492.988
https://doi.org/10.1093/ofid/ofac492.988
Autor:
Florian A. Lempp, Tassilo Volz, Elisabetta Cameroni, Fabio Benigni, Jiayi Zhou, Laura E. Rosen, Julia Noack, Fabrizia Zatta, Hannah Kaiser, Siro Bianchi, Gloria Lombardo, Stefano Jaconi, Hasan Imam, Leah B. Soriaga, Nadia Passini, David M. Belnap, Andreas Schulze, Marc Lütgehetmann, Amalio Telenti, Andrea L. Cathcart, Gyorgy Snell, Lisa A. Purcell, Christy M. Hebner, Stephan Urban, Maura Dandri, Davide Corti, Michael A. Schmid
Background & AimsChronic hepatitis B is a major global public health problem, and coinfection with hepatitis delta virus (HDV) worsens disease outcome. Here, we describe a hepatitis B virus (HBV) surface antigen (HBsAg)-targeting monoclonal antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fec46ca7004efc0b3dbdb32e584ca22
https://doi.org/10.1101/2022.09.09.507326
https://doi.org/10.1101/2022.09.09.507326
Autor:
Yesseinia I. Anglero-Rodriguez, Florian A. Lempp, James McIninch, Mark K. Schlegel, Christopher R. Brown, Donald J. Foster, Adam B. Castoreno, Tuyen Nguyen, Megha Subramanian, Martin Montiel-Ruiz, Hannah Kaiser, Anna Sahakyan, Roberto Spreafico, Svetlana Shulga Morskaya, Joseph D. Barry, Daniel Berman, Stephanie Lefebvre, Anne Kasper, Timothy Racie, Diann Weddle, Melissa Mobley, Arlin Rogers, Joseph Dybowski, Saeho Chong, Jayaprakash Nair, Amy Simon, Kevin Sloan, Seungmin Hwang, Herbert W. Virgin, Kevin Fitzgerald, Martin A. Maier, Gregory Hinkle, Christy M. Hebner, Akin Akinc, Vasant Jadhav
RNA interference is a natural antiviral mechanism that could be harnessed to combat SARS-CoV-2 infection by targeting and destroying the viral genome. We screened lipophilic small-interfering RNA (siRNA) conjugates targeting highly conserved regions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fd2ebe031d135cd9e0bfc23cecf5156
https://doi.org/10.1101/2022.03.20.485044
https://doi.org/10.1101/2022.03.20.485044
Autor:
Anil, Gupta, Yaneicy, Gonzalez-Rojas, Erick, Juarez, Manuel, Crespo Casal, Jaynier, Moya, Diego R, Falci, Elias, Sarkis, Joel, Solis, Hanzhe, Zheng, Nicola, Scott, Andrea L, Cathcart, Christy M, Hebner, Jennifer, Sager, Erik, Mogalian, Craig, Tipple, Amanda, Peppercorn, Elizabeth, Alexander, Phillip S, Pang, Almena, Free, Cynthia, Brinson, Melissa, Aldinger, Adrienne E, Shapiro, Luis, Zepeda
Publikováno v:
The New England journal of medicine. 385(21)
Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b5f445ae6fb12ebf06154da972781a2
https://pubmed.ncbi.nlm.nih.gov/35294998
https://pubmed.ncbi.nlm.nih.gov/35294998
Autor:
Jason A. Wojcechowskyj, Marcel Meury, Dora Pinto, Exequiel Dellota, Fabio Benigni, Jesse D. Bloom, M. Alejandra Tortorici, Florian A. Lempp, Anna De Marco, Josh Dillen, Christy M. Hebner, Amin Addetia, Fabrizia Zatta, Laura E. Rosen, Elisabetta Cameroni, Nadine Czudnochowski, Amalio Telenti, Johan Neyts, Stefano Jaconi, Allison J. Greaney, Zhuoming Liu, Patrick Hernandez, John E. Bowen, Roberta Marzi, Jiayi Zhou, Maria L. Agostini, Hannah Kaiser, William G. Glass, Rana Abdelnabi, Ivy Zhang, Tristan I. Croll, Adam S. Dingens, Gyorgy Snell, Shi-Yan Caroline Foo, Davide Corti, Luca Piccoli, Martin Montiel-Ruiz, David Veesler, Sean P. J. Whelan, Gloria Lombardo, Herbert W. Virgin, Martina Beltramello, Colin Havenar-Daughton, Spencer Stumpf, Tyler N. Starr, Michael P. Housley, Jessica Bassi, John D. Chodera, Katja Culap, Nicole Sprugasci, Julia di Iulio, Chiara Silacci-Fregni, Matteo Samuele Pizzuto, Alexandra C. Walls, Young-Jun Park, Jay C. Nix, Heather Tucker
Publikováno v:
Nature
Nature, vol 597, iss 7874
Nature, vol 597, iss 7874
An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape1–3, have activity against diverse sarbecoviruses4–7, and be highly protective through viral neutralization8–11 and effector functions12,13. Understanding how these properti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea33aa8d0b103b0c5bd075c01c53fa5a
https://europepmc.org/articles/PMC9282883/
https://europepmc.org/articles/PMC9282883/
Autor:
Anil Gupta, Erik Mogalian, Yaneicy Gonzalez-Rojas, Manuel Crespo Casal, Melissa Aldinger, Elizabeth Alexander, Elias Sarkis, Amanda Peppercorn, Hanzhe Zheng, Christy M. Hebner, Joel Solis, Nicola Scott, Craig Tipple, Andrea L. Cathcart, Diego R. Falci, Adrienne E. Shapiro, Almena Free, Jennifer Sager, Jaynier Moya, Phillip S. Pang, Cynthia Brinson, Erick Juarez
BackgroundCoronavirus disease 2019 (Covid-19) disproportionately results in hospitalization and death in older patients and those with underlying comorbidities. Sotrovimab is a pan-sarbecovirus monoclonal antibody designed to treat such high-risk pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdcbc8747e377498858eb2160f81d3a4
https://doi.org/10.1101/2021.05.27.21257096
https://doi.org/10.1101/2021.05.27.21257096
Autor:
Andrea L. Cathcart, Colin Havenar-Daughton, Florian A. Lempp, Daphne Ma, Michael A. Schmid, Maria L. Agostini, Barbara Guarino, Julia Di iulio, Laura E. Rosen, Heather Tucker, Joshua Dillen, Sambhavi Subramanian, Barbara Sloan, Siro Bianchi, Dora Pinto, Christian Saliba, Katja Culap, Jason A Wojcechowskyj, Julia Noack, Jiayi Zhou, Hannah Kaiser, Sooyoung Lee, Nisar Farhat, Arthur Chase, Martin Montiel-Ruiz, Exequiel Dellota, Arnold Park, Roberto Spreafico, Anna Sahakyan, Elvin J. Lauron, Nadine Czudnochowski, Elisabetta Cameroni, Sarah Ledoux, Yoshihiro Kawaoka, Adam Werts, Christophe Colas, Leah Soriaga, Amalio Telenti, Lisa A. Purcell, Seungmin Hwang, Gyorgy Snell, Herbert W. Virgin, Davide Corti, Christy M. Hebner
VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 and VIR-7832 were derived from a parent antibody (S309) isolated from memory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a80fd146e1b2084c931712710b2229b0
https://doi.org/10.1101/2021.03.09.434607
https://doi.org/10.1101/2021.03.09.434607
Autor:
Christy M Hebner, Bin Han, Katherine M Brendza, Michelle Nash, Maisoun Sulfab, Yang Tian, Magdeleine Hung, Wanchi Fung, Randall W Vivian, James Trenkle, James Taylor, Kyla Bjornson, Steven Bondy, Xiaohong Liu, John Link, Johan Neyts, Roman Sakowicz, Weidong Zhong, Hengli Tang, Uli Schmitz
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e39163 (2012)
Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. The mechanism of action of TGV has not been clearly defined despite the identific
Externí odkaz:
https://doaj.org/article/eeeef54f94cb49e4bd1ec7bb38024a99
Autor:
David K. Hong, Anna De Marco, Andrea Minola, Katja Culap, Alessia Peter, Christy M. Hebner, Matteo Samuele Pizzuto, Fabrizia Zatta, Aurelio Bonavia, Fabio Benigni, Nadia Passini, Davide Corti, Siro Bianchi, Leah Soriaga, Barbara Guarino
Publikováno v:
Open Forum Infectious Diseases
Background Influenza A viruses are responsible for seasonal epidemics and represent a constant pandemic threat. Influenza vaccines induce predominantly antibodies against the head region of hemagglutinin (HA) and are strain specific. Vaccine effectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5149fea4aa905635f0a563c95e926ddd
https://doi.org/10.1093/ofid/ofaa439.1416
https://doi.org/10.1093/ofid/ofaa439.1416
Autor:
Lee Swem, Alisa W Serio, Chris M. Pillar, Amanda Burek, Danielle Hall, Frederick Cohen, Ryan Cirz, Kevin M. Krause, Eliana Saxon Armstrong, Christy M. Hebner, Adrian Jubb, Lynn Miesel, Grace Lee, Vincent Nieto, Mary Thwaites, Darrin Hildebrandt, Cat M. Haglund, Machajewski Timothy D, Timothy R. Kane, Meredith Hackel, Logan D. Andrews
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
New drugs with novel mechanisms of resistance are desperately needed to address both community and nosocomial infections due to Gram-negative bacteria. One such potential target is LpxC, an essential enzyme that catalyzes the first committed step of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aacedbcf86b22e6e1952bd3b6c32722d
https://doi.org/10.1128/aac.00977-19
https://doi.org/10.1128/aac.00977-19